Review
Oncology
Kamil Jozef Synoradzki, Ewa Bartnik, Anna M. Czarnecka, Michal Fiedorowicz, Wiktoria Firlej, Anna Brodziak, Agnieszka Stasinska, Piotr Rutkowski, Pawel Grieb
Summary: The treatment of osteosarcoma has remained unchanged for approximately 30 years apart from chemotherapy modifications. This article focuses on the possibility of targeting p53 in the treatment of osteosarcoma, highlighting data collection from patient samples, animal models, molecular interactions, and gene therapy. It offers hope for future changes in osteosarcoma treatment methods based on TP53 targeting.
Review
Oncology
Shizhe Li, He Zhang, Jinxin Liu, Guanning Shang
Summary: In this paper, the molecular mechanisms, related targets, and clinical applications of targeted osteosarcoma therapy are reviewed. It provides a summary of the characteristics of targeted osteosarcoma therapy, the advantages of its clinical application, and the future development of targeted therapy. Targeted therapy shows potential in the treatment of osteosarcoma and may offer an important means of precise and personalised treatment in the future, but drug resistance and adverse effects may limit its application.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Qing Yang, Jiemiao Hu, Zhiliang Jia, Qi Wang, Jing Wang, Long Hoang Dao, Wendong Zhang, Sheng Zhang, Xueqing Xia, Richard Gorlick, Shulin Li
Summary: This study proposes a new cell therapy for treating osteosarcoma. By introducing a specific protein into peripheral blood mononuclear cells, tumor growth can be effectively inhibited without observable toxicity.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Stefano Scalera, Marco Mazzotta, Giacomo Corleone, Francesca Sperati, Irene Terrenato, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Patrizia Vici, Enzo Gallo, Simonetta Buglioni, Paolo Visca, Edoardo Pescarmona, Daniele Marinelli, Francesca De Nicola, Ludovica Ciuffreda, Frauke Goeman, Maurizio Fanciulli, Raffaele Giusti, Andrea Vecchione, Ruggero De Maria, Federico Cappuzzo, Paolo Marchetti, Gennaro Ciliberto, Marcello Maugeri-Sacca
Summary: The study explored the impact of KEAP1/STK11 alterations on immunotherapy efficacy in lung adenocarcinoma, revealing the importance of multimodal data integration for clinically exploitable taxonomy. Subtyping based on KEAP1/TP53 mutations identified distinct molecular and clinical characteristics, with different survival outcomes observed in KEAP1 single-mutant and KEAP1/TP53 double-mutant tumors in two independent cohorts.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Yingqian Chen, Runzhi Liu, Wei Wang, Chen Wang, Ning Zhang, Xuejing Shao, Qiaojun He, Meidan Ying
Summary: Osteosarcoma, a highly malignant tumor with widespread genetic abnormalities, can be stratified into molecular subtypes for targeted therapy. Molecular classification based on genetic characteristics helps in achieving better therapeutic responses and moving towards personalized medicine.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Immunology
Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang, Erlei Zhang
Summary: Cholangiocarcinoma (CCA) is a rare and aggressive type of cancer with increasing incidence in recent years. Surgery is the most effective treatment, but not suitable for all patients. Targeted therapy focusing on FGFR, IDH, and EGFR2, as well as immunotherapy with PD-1 inhibitors, CAR-T cells, and TILs, have shown promising results in CCA treatment. Combining targeted therapy, immunotherapy, and conventional chemotherapy can greatly improve the prognosis of advanced CCA patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Zunguo Hu, Shuang Wen, Zijun Huo, Qing Wang, Jiantao Zhao, Zihao Wang, Yanchun Chen, Lingyun Zhang, Fenghua Zhou, Zhangyu Guo, Huancai Liu, Shuanhu Zhou
Summary: Osteosarcoma is a highly malignant tumor with mechanisms that are not well understood. Current treatment methods are ineffective, while targeted therapy is becoming an important direction for development.
Article
Chemistry, Multidisciplinary
Xin Huang, Wei Wu, Doudou Jing, Lingkai Yang, Haoyu Guo, Lutong Wang, Weiyue Zhang, Feifei Pu, Zengwu Shao
Summary: This study demonstrates the potential therapeutic effects of engineered exosomes as targeted delivery vehicles for lncRNA MEG3 in osteosarcoma. The engineered exosomes cRGD-Exo-MEG3 efficiently deliver MEG3 to tumor cells, significantly enhancing its anti-tumor effects.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Cell Biology
Yun Liu, Nenggan Huang, Shijie Liao, Emel Rothzerg, Felix Yao, Yihe Li, David Wood, Jiake Xu
Summary: Osteosarcoma is the most common primary malignant bone tumor, with incidence peaking during adolescence. Despite improvements in prognosis with the introduction of neoadjuvant chemotherapy, outcomes have not significantly improved since then. Novel therapeutic strategies are urgently needed as an adjunct to conventional treatment modalities to improve outcomes for patients with osteosarcoma.
CELL PROLIFERATION
(2021)
Review
Medicine, General & Internal
Pampina Pilavaki, Amir Gahanbani Ardakani, Panagiotis Gikas, Anastasia Constantinidou
Summary: Osteosarcoma is a rare malignancy arising from mesenchymal tissue and is the most common bone sarcoma. The management of osteosarcoma is challenging and requires a multidisciplinary approach. Surgical, radiotherapy, and chemotherapy are the main treatment options, but there is a need for novel therapeutic strategies to improve outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Nanoscience & Nanotechnology
Zhongmin Li, Yilun Liu, Xuedong Fang, Zhenbo Shu
Summary: Molecular targeted therapy not only directly inhibits the proliferation and metastasis of tumor cells, but also activates the immune system through various mechanisms. However, limitations such as poor water solubility, insufficient accumulation at the tumor site, and nonspecific targeting of immune cells hinder their application. Innovative nanomaterials have been developed to overcome these obstacles and enhance the immunomodulatory effects of molecular targeted drugs.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Oncology
Flavio G. Rocha
Summary: Pancreatic cancer is an aggressive gastrointestinal malignancy, and recent genomic studies have identified key driver mutations that can be targeted for therapy. Advances in cancer immunology have also shown potential for utilizing the host's immune system for treatment. However, the unique fibrotic stroma of pancreatic cancer presents challenges in translating these strategies to clinical practice.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Nanoscience & Nanotechnology
Jia-Xin Cai, Ji-Hua Liu, Jun-Yong Wu, Yong-Jiang Li, Xiao-Han Qiu, Wen-Jie Xu, Ping Xu, Da-Xiong Xiang
Summary: This study developed a targeted nano-carrier and evaluated its anti-cancer efficacy both in vitro and in vivo. The results demonstrated that the nano-carrier successfully delivered the drug to osteosarcoma cells and exhibited significant anti-cancer effects, while causing minimal damage to normal tissues.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Materials Science, Multidisciplinary
Xiaokai Chen, Xiaodong Zhang, Yinglong Wu, Yun Chen, Yi Guo, Deblin Jana, Dongdong Wang, Wei Yuan, Yanli Zhao
Summary: In this study, a multifunctional nanoscavenger was designed to clear tumor extracellular matrix, improve tumor hypoxia, and enhance photodynamic and immune therapies. This strategy provides a solution to overcome the suppressive tumor microenvironment.
Article
Nanoscience & Nanotechnology
Xin Yao, Qingyu Wang, Changge Han, Jiaojiao Nie, Yaotian Chang, Lipeng Xu, Bingya Wu, Jingtian Yan, Zhiyuan Chen, Wei Kong, Yuhua Shi, Yaming Shan
Summary: Broadly neutralizing antibodies (bNAbs) can neutralize genetically diverse human immunodeficiency virus (HIV) strains. Passive immunization provides potential protection against HIV infection in animal models. However, direct antibody infusion is limited by short half-life and deficient immunogenicity. As an alternative strategy, we propose using nano viral vectors, specifically adeno-associated virus (AAV), to continuously produce bNAbs against HIV.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Review
Oncology
Douglas J. Harrison, David S. Geller, Jonathan D. Gill, Valerae O. Lewis, Richard Gorlick
EXPERT REVIEW OF ANTICANCER THERAPY
(2018)
Article
Gastroenterology & Hepatology
Daniel M. Green, Mingjuan Wang, Matthew J. Krasin, DeoKumar Srivastava, Mary V. Relling, Carrie R. Howell, Kirsten K. Ness, Sue C. Kaste, William Greene, Dennis W. Jay, Israel Fernandez-Pineda, Ching-Hon Pui, Sima Jeha, Michael W. Bishop, Wayne L. Furman, Leslie L. Robison, Melissa M. Hudson
Article
Oncology
Zachary E. Stiles, Paxton V. Dickson, Evan S. Glazer, Andrew J. Murphy, Andrew M. Davidoff, Stephen W. Behrman, Michael W. Bishop, Michael G. Martin, Jeremiah L. Deneve
JOURNAL OF SURGICAL ONCOLOGY
(2018)
Article
Oncology
Ingrid Tonning Olsson, Tara M. Brinkman, Mingjuan Wang, Matthew J. Ehrhardt, Pia Banerjee, Daniel A. Mulrooney, I-Chan Huang, Kirsten K. Ness, Michael W. Bishop, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Kevin R. Krull
Article
Oncology
Hadeel Halalsheh, Sue C. Kaste, Matthew J. Krasin, April Sykes, Natasha Sahr, Sheri L. Spunt, Sara M. Federico, Michael W. Bishop
PEDIATRIC BLOOD & CANCER
(2020)
Article
Oncology
Michael W. Bishop, Kirsten K. Ness, Chenghong Li, Wei Liu, Deo Kumar Srivastava, Wassim Chemaitilly, Kevin R. Krull, Daniel M. Green, Alberto S. Pappo, Leslie L. Robison, Melissa M. Hudson, Daniel A. Mulrooney
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2020)
Article
Oncology
Ingrid Tonning Olsson, Nicole M. Alberts, Chenghong Li, Matthew J. Ehrhardt, Daniel A. Mulrooney, Wei Liu, Alberto S. Pappo, Michael W. Bishop, Doralina L. Anghelescu, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Kirsten K. Ness, Kevin R. Krull, Tara M. Brinkman
Summary: Survivors of childhood cancer are at risk of chronic pain, which is associated with impaired neurocognition, physical performance, social functioning, and health-related quality of life. Screening for pain and interventions targeting pain interference are essential for improving the overall well-being of these survivors.
Review
Oncology
Jonathan Gill, Richard Gorlick
Summary: Osteosarcoma, the most common primary bone cancer in children and young adults, presents challenges in treatment due to its rarity and molecular heterogeneity. Collaborative efforts in biological discoveries, technologies, and therapeutic approaches are expected to advance osteosarcoma treatment and improve patient outcomes. The increasing feasibility of molecular profiling, along with the creation of robust model systems and large tissue banks, has enhanced understanding of osteosarcoma biology.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Oncology
Anderson B. Collier, Mark D. Krailo, Ha M. Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa R. Bomgaars, Damon R. Reed, Richard G. Gorlick, Katherine A. Janeway
Summary: Analysis of seven Children's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors showed a 6-month event-free survival (EFS) of 12.7% for relapsed/progressive Ewing sarcoma patients, indicating poor outcomes. Despite docetaxel achieving its protocol-specified radiographic response rate, its EFS was similar to other agents, suggesting that a higher radiographic response rate may not lead to superior disease control. This EFS benchmark could be used as an additional endpoint in trials for recurrent Ewing sarcoma.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Cell Biology
Xin Zhou, Allyson Beilter, Zhaohui Xu, Ruli Gao, Shunbin Xiong, Adriana Paulucci-Holthauzen, Guillermina Lozano, Benoit de Crombrugghe, Richard Gorlick
Summary: This study identified chondrocytes as an additional source for mesenchymal progenitor cells (MPCs) and showed that Wnt/ss-catenin pathway discretely regulates the development from chondrocytes to C-MPC and subsequently from C-MPC to osteoblasts. Furthermore, the study unveiled a previously unrecognized functional link between ss-catenin and p53, with p53 playing a negative role in MPC osteogenic differentiation induced by Wnt/ss-catenin signaling.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Qing Yang, Jiemiao Hu, Zhiliang Jia, Qi Wang, Jing Wang, Long Hoang Dao, Wendong Zhang, Sheng Zhang, Xueqing Xia, Richard Gorlick, Shulin Li
Summary: This study proposes a new cell therapy for treating osteosarcoma. By introducing a specific protein into peripheral blood mononuclear cells, tumor growth can be effectively inhibited without observable toxicity.
CLINICAL CANCER RESEARCH
(2022)
Correction
Medicine, General & Internal
Hannah C. Beird, Stefan S. Bielack, Adrienne M. Flanagan, Jonathan Gill, Dominique Heymann, Katherine A. Janeway, J. Andrew Livingston, Ryan D. Roberts, Sandra J. Strauss, Richard Gorlick
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Medicine, General & Internal
Hannah C. Beird, Stefan S. Bielack, Adrianne M. Flanagan, Jonathan Gill, Dominique Heymann, Katherine A. Janeway, J. Andrew Livingston, Ryan D. Roberts, Sandra J. Strauss, Richard Gorlick
Summary: Osteosarcoma is the most common primary malignant bone tumor with a bimodal incidence peaking at 18 and 60 years of age. It is more common in males and is driven by genetic factors related to bone formation leading to malignant progression and metastasis. Screening is currently focused on high-risk groups, and the prognosis for patients with metastatic disease remains poor.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Biochemistry & Molecular Biology
Jiayi Sun, Wing-Yuk Chow, Gufeng Xu, M. John Hicks, Manjula Nakka, Jianhe Shen, Patrick Kwok Shing M. Ng, Aaron Taylor, Alexander E. Yu, Jason A. Farrar, Donald Barkauskas, Richard M. Gorlick, Jaime M. Guidry Auvil, Daniela Gerhard, Paul Meltzer, Rudy Guerra, Tsz-Kwong C. Man, Ching Lau, TARGET Osteosarcoma Consortium
Summary: Osteosarcoma is a primary malignant bone tumor that commonly metastasizes to the lungs. Altered FAS expression due to DNA methylation has been explored as a mechanism in cancer cells. Analysis revealed high variability in methylation of CpG sites that correlated with FAS mRNA expression. Treatment with demethylating agent 5-azacytidine restored FAS protein expression and reduced metastasis in osteosarcoma cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid, Victor M. Santana